Lummy Pharmaceuticals has continuously received a Wind ESG BBB rating, with a comprehensive score of 6.77

According to Tongbi Finance, on May 29, 2026, Chongqing Lummy Pharmaceutical Co., Ltd. (stock abbreviation: Lummy Pharmaceutical, code: 300006.SZ) received a Wind ESG rating of BBB, unchanged from the previous period. The company's overall score is 6.77, higher than the pharmaceutical industry average of 5.85. It ranks 67th among 280 companies in the pharmaceutical industry, placing it in the top 23.93% of the industry. The scores for the environmental, social, and governance dimensions are 4.43, 5.09, and 6.74, respectively.

Compared to the previous rating, the overall score increased from 6.45 to 6.77, an improvement of 0.32 points. The contribution from management practices rose from 3.46 to 3.77, an increase of 0.31 points. The contribution from controversy events remained stable at 3.00. In terms of dimensions, the environmental dimension improved by 0.62 points, the social dimension decreased by 0.46 points, and the governance dimension increased by 1.95 points.

Rating Observation

In the environmental dimension, the company has established a relatively systematic management framework for waste and wastewater management and disclosed key performance data. The company has formulated the "Pollutant Prevention and Control Management System" and the "Wastewater Discharge Control Management System," and equipped with wastewater treatment systems and exhaust gas treatment devices to ensure compliant operation. In terms of waste management, the total amount of hazardous waste generated by the company is 218.33 tons, with a hazardous waste generation rate of 28.15 tons/CNY per hundred million in revenue, and has established a ledger for the collection, temporary storage, and transfer of hazardous waste. In wastewater management, the company disclosed a wastewater discharge volume of 115,903 tons, with a wastewater discharge rate of 149.42 tons/CNY per million in revenue, and achieved compliant discharge through centralized treatment facilities. Additionally, the company has specified concrete measures for the comprehensive utilization and classified treatment of waste and wastewater. Relevant information on exhaust gas management and raw material management has also been disclosed, but information on the use of green materials and the reduction of toxic substances still needs improvement.

In the social dimension, the company focuses on research and innovation, demonstrating strong technical capabilities and product quality management levels. The company is the first in the southwestern region to obtain certification for its intellectual property management system, with R&D investment accounting for 13.55% of operating revenue, and a total of 95 effective patents, with an effective patent count of 12.25 per hundred million in revenue. The company strictly adheres to GMP drug production quality management standards and has established a comprehensive quality management system, achieving a first-pass qualification rate of ≥97.0% for powder injection products and a market sampling pass rate of 100%. Furthermore, the company has developed the "Product Recall Management Procedures" and ensures the efficient operation of the recall mechanism through regular simulation drills. Employee training coverage reaches 100%, with an average training duration of 11 hours per person, covering multi-level skill enhancement and leadership development courses. However, there are still certain gaps in the disclosure of customer management systems and employment areas, particularly regarding customer management certification and employee turnover rates.

In the governance dimension, the company demonstrates certain governance capabilities in board independence and anti-corruption management. The board consists of 9 members, with an independent director ratio of 33.33%, and there are no independent directors serving for more than 6 years or holding positions in more than 3 listed companies. The CEO does not concurrently serve as chairman, reflecting a governance check-and-balance mechanism The attendance rate of board members reached 100%, and there are audit, compensation, and nomination committees, with 100% of the compensation committee being independent directors. The company has established the "Anti-Corruption and Anti-Commercial Bribery System (Trial)" and a "Compliance Manual," and has provided integrity education to 131 employees. Additionally, an antitrust and fair competition management system has been set up, with regular risk assessments and internal audits conducted. The proportion of female directors is 22.22%, and the proportion of female executives is 33.33%, reflecting a certain degree of diversity. However, the dissent rate for audit proposals is relatively high (11.90%), which may indicate shareholders' concerns regarding certain governance matters. Furthermore, information related to the risk management committee and reporting mechanisms has not yet been disclosed.

Content generated by AI on May 29, 2026, please verify important information